These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18840733)

  • 21. Lessons from the Pacific programme to eliminate lymphatic filariasis: a case study of 5 countries.
    Huppatz C; Capuano C; Palmer K; Kelly PM; Durrheim DN
    BMC Infect Dis; 2009 Jun; 9():92. PubMed ID: 19523192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caring for patients in the global programme to eliminate lymphatic filariasis.
    Mackenzie CD; Mante S
    Int Health; 2020 Dec; 13(Suppl 1):S48-S54. PubMed ID: 33349884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How Thailand eliminated lymphatic filariasis as a public health problem.
    Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
    Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained reduction in prevalence of lymphatic filariasis infection in spite of missed rounds of mass drug administration in an area under mosquito nets for malaria control.
    Njenga SM; Mwandawiro CS; Wamae CN; Mukoko DA; Omar AA; Shimada M; Bockarie MJ; Molyneux DH
    Parasit Vectors; 2011 May; 4():90. PubMed ID: 21612649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.
    Antony Oliver MC; Graham M; Gass KM; Medley GF; Clark J; Davis EL; Reimer LJ; King JD; Pouwels KB; Hollingsworth TD
    Clin Infect Dis; 2024 Apr; 78(Supplement_2):S160-S168. PubMed ID: 38662697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria.
    Richards FO; Eigege A; Miri ES; Kal A; Umaru J; Pam D; Rakers LJ; Sambo Y; Danboyi J; Ibrahim B; Adelamo SE; Ogah G; Goshit D; Oyenekan OK; Mathieu E; Withers PC; Saka YA; Jiya J; Hopkins DR
    PLoS Negl Trop Dis; 2011 Oct; 5(10):e1346. PubMed ID: 22022627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs.
    Mathew CG; Bettis AA; Chu BK; English M; Ottesen EA; Bradley MH; Turner HC
    Clin Infect Dis; 2020 Jun; 70(12):2561-2567. PubMed ID: 31343064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continental-scale, data-driven predictive assessment of eliminating the vector-borne disease, lymphatic filariasis, in sub-Saharan Africa by 2020.
    Michael E; Singh BK; Mayala BK; Smith ME; Hampton S; Nabrzyski J
    BMC Med; 2017 Sep; 15(1):176. PubMed ID: 28950862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007).
    Chu BK; Hooper PJ; Bradley MH; McFarland DA; Ottesen EA
    PLoS Negl Trop Dis; 2010 Jun; 4(6):e708. PubMed ID: 20532228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors associated with failing pre-transmission assessment surveys (pre-TAS) in lymphatic filariasis elimination programs: Results of a multi-country analysis.
    Burgert-Brucker CR; Zoerhoff KL; Headland M; Shoemaker EA; Stelmach R; Karim MJ; Batcho W; Bougouma C; Bougma R; Benjamin Didier B; Georges N; Marfo B; Lemoine JF; Pangaribuan HU; Wijayanti E; Coulibaly YI; Doumbia SS; Rimal P; Salissou AB; Bah Y; Mwingira U; Nshala A; Muheki E; Shott J; Yevstigneyeva V; Ndayishimye E; Baker M; Kraemer J; Brady M
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008301. PubMed ID: 32479495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National mass drug administration costs for lymphatic filariasis elimination.
    Goldman AS; Guisinger VH; Aikins M; Amarillo ML; Belizario VY; Garshong B; Gyapong J; Kabali C; Kamal HA; Kanjilal S; Kyelem D; Lizardo J; Malecela M; Mubyazi G; Nitièma PA; Ramzy RM; Streit TG; Wallace A; Brady MA; Rheingans R; Ottesen EA; Haddix AC
    PLoS Negl Trop Dis; 2007 Oct; 1(1):e67. PubMed ID: 17989784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis.
    Krentel A; Fischer PU; Weil GJ
    PLoS Negl Trop Dis; 2013 Nov; 7(11):e2447. PubMed ID: 24278486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The significant scale up and success of Transmission Assessment Surveys 'TAS' for endgame surveillance of lymphatic filariasis in Bangladesh: One step closer to the elimination goal of 2020.
    Shamsuzzaman AK; Haq R; Karim MJ; Azad MB; Mahmood AS; Khair A; Rahman MM; Hafiz I; Ramaiah KD; Mackenzie CD; Mableson HE; Kelly-Hope LA
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005340. PubMed ID: 28141812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphatic Filariasis Elimination in American Samoa: Evaluation of Molecular Xenomonitoring as a Surveillance Tool in the Endgame.
    Lau CL; Won KY; Lammie PJ; Graves PM
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005108. PubMed ID: 27802280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of the monitoring and evaluation strategies to support the World Health Organization's Global Programme to Eliminate Lymphatic Filariasis.
    Lammie PJ; Gass KM; King J; Deming MS; Addiss DG; Biswas G; Ottesen EA; Henderson R
    Int Health; 2020 Dec; 13(Suppl 1):S65-S70. PubMed ID: 33349883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.
    Ojha CR; Joshi B; Kc KP; Dumre SP; Yogi KK; Bhatta B; Adhikari T; Crowley K; Marasini BR
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005788. PubMed ID: 28723904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India.
    Sabesan S; Krishnamoorthy K; Hoti SL; Subramanian S; Srividya A; Roy N; Jain T; Kumar A; Rahi M
    Indian J Med Res; 2022 Mar; 155(3&4):347-355. PubMed ID: 36124509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of microfilaremia in 'hotspots' of four lymphatic filariasis endemic districts of Nepal during post-MDA surveillance.
    Mehta PK; Maharjan M
    PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011932. PubMed ID: 38295107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.
    de Souza DK; Ahorlu CS; Adu-Amankwah S; Otchere J; Mensah SK; Larbi IA; Mensah GE; Biritwum NK; Boakye DA
    Trials; 2017 Oct; 18(1):448. PubMed ID: 28969715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.